top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
23/09/2026 Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy Immunovant’s IMVT-1402 failed to meet the primary endpoint in CLE Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy (Ref) Roche reported positive prespecified interim results from Ph3 IMAgINATION study of sefaxersen (ASO targeting complement factor B) in adults with primary IgA nephropathy (IgAN). The trial met its primary endpoint, demonstrating statistically significant
decodeMR Team
Sep 231 min read
bottom of page